Study: Global Consumption Of Antibiotics Rising, In Particular In LMICs; Policy Change Needed 12/04/2018 Catherine Saez In the face of the growing threat of antimicrobial resistance, a recent study of the Proceedings of the National Academy of Sciences of the United States of America (PNSA) found that the antibiotic consumption rate in low and middle-income countries has substantially increased in recent years. At the same time, inequities in drug access persist in many countries, with high rates of infectious disease-related mortality, according to the study. Continue reading -> At Geneva Health Forum: Importance Of High Quality Of Health Systems, Beyond Access 11/04/2018 Catherine Saez Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
At Geneva Health Forum: Importance Of High Quality Of Health Systems, Beyond Access 11/04/2018 Catherine Saez Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 Catherine Saez How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Posts navigation Older postsNewer posts